Alt-protein
-
DATABASE (44)
-
ARTICLES (132)
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
CEO and founder of Mycorena
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
CEO and founder of Plantruption
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Co-founder of Xampla
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Interview with Qlue CEO, part II: Smart cities in Indonesia and beyond
Continuing from the first part of an interview, Qlue CEO Rama Raditya discusses trends, achievements and challenges in smart city development
Future Food Asia 2021: Two winners take home $100,000 each
Agrifood startups, corporations and investors urged to collaborate and take action, tackling challenges in nutrition and climate change
SWITCH Singapore: Sustainability startups see growing demand from corporates
Sophie’s BioNutrients, Ubiik and Intello Labs also note new trends in technology and supply chain arising from the Covid-19 pandemic, across the food, manufacturing and e-commerce sectors
Senior Deli: Creating easy-to-swallow, appealing food for dysphagia sufferers
Already supplying to over 200 senior homes and hospitals, the Future Food Asia 2021 co-winner uses proprietary tech to make nutritious, affordable texture-modified foods for people with swallowing difficulties
Interview with Qlue CEO: "We didn't know what a smart city should look like"
Co-founder and CEO of Qlue, Indonesia's largest "smart city" company, Rama Raditya explains how citizen involvement – not high-tech – is the true innovation of smart cities and the agent for change; plus how his startup has grown from partnering governments to businesses, and more
Geometry Healthcare: Smart toilets that warn you if you are sick, or at risk
Using a biochip for urinalysis and offline health management services, Geometry Healthcare aims to differentiate itself in the smart toilet business
Meatable joins Royal DSM to create growth media specific for cell-based meat tech
The R&D between the biotech startup and fellow Dutch nutrition conglomerate could help scale and drive the commercial viability of lab-grown meat
Agate learns it's not all about the games – it's about the fun
Agate has evolved into one of the biggest game development companies in Indonesia over the past decade. We learned how it got there from Shieny Aprilia, Agate's Vice President of Enterprise Business
Biomilq: Creating cell-based mothers’ milk in a lab
With the aim of helping women struggling to breastfeed, Bill Gates-backed Biomilq is disrupting the $45bn baby formula industry developing lab-grown breast milk from mammary epithelial cells
Venturra Capital's Raditya Pramana: Bear market "very close now"
In an interview, the Indonesian VC firm's newest partner also charts out the course for their new fund, Venturra Discovery
Cubiq Foods: Bioreactor farms producing the food of tomorrow
Growing appetite for meat alternatives expected to fuel demand for Cubiq’s low calorie, Omega 3-enriched lab-grown fats
Allozymes wants to supercharge manufacturing with engineered enzymes
The Future Food Asia 2021 award winner speeds up enzyme engineering from years to months, is already attracting clients and has just raised $5m seed funding
European agritech is the new global focus, as startup investments nearly doubled in 2019
Last year, European agritech surpassed China for the first time in investments received, with openings in multiple subsectors from big data to blockchain
In China's frothy tea drink universe, startups learn to battle
Tea shop startups like Nayuki and Heytea are staying afloat by turning to high-quality organic ingredients and greater brand visibility
Plant-based eggs (Part II): The foodtech startups to watch
Here’s a shortlist of the foodtech startups to watch in the global vegan egg market
Sorry, we couldn’t find any matches for“Alt-protein”.
POPULAR DATABASE
